STOCK TITAN

XORTX Therapeutics Inc. - XRTX STOCK NEWS

Welcome to our dedicated page for XORTX Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics stock.

XORTX Therapeutics Inc. (NASDAQ: XRTX) is a bio-pharmaceutical company dedicated to developing and commercializing innovative therapies aimed at treating progressive kidney diseases worldwide. Headquartered in Calgary, Canada, XORTX focuses on addressing serious health conditions related to aberrant purine and uric acid metabolism, including diabetic nephropathy, polycystic kidney disease (PKD), and complications arising from diabetes and cardiovascular diseases.

The company has two lead programs targeting progressive kidney disease due to diabetes and PKD. Additionally, XORTX is actively involved in the development of uric acid-lowering agents to treat conditions like hypertension, insulin resistance, metabolic syndrome, and diabetes. Their pipeline includes xanthine oxidase inhibitors that show potential in managing diabetic nephropathy.

One of XORTX's strategic milestones is its alliance with Teijin Pharma Limited for the development of TMX-049, a promising xanthine oxidoreductase inhibitor. Another significant partnership is with the Icahn School of Medicine, focusing on studying acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

XORTX Therapeutics Inc. is at the clinical-stage of biotechnology, aiming to identify, develop, and potentially commercialize therapies that can slow or reverse the progression of chronic kidney diseases. Their focus includes addressing the immediate needs of individuals facing acute kidney injury (AKI) due to respiratory virus infections and exploring other opportunities where their intellectual property can mitigate various health issues.

Rhea-AI Summary

XORTX Therapeutics, a late-stage clinical pharmaceutical company focused on treating progressive kidney disease, announces its participation in the BIO International Convention 2024 from June 3-6 at the San Diego Convention Center. CEO Dr. Allen Davidoff will present an overview of the company's progress and future plans on June 4 at 3:30 pm in Theater 1. The event aims to foster outreach to pharmaceutical partners and industry contacts, with over 25 meetings scheduled. One-on-one meetings with Dr. Davidoff can be arranged through the BIO International 2024 meeting platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
conferences
-
Rhea-AI Summary

XORTX Therapeutics announced the repricing of warrants issued in October 2021, receiving approval from the TSX Venture Exchange to amend the terms. The repricing affects 101,111 warrants post a 9:1 consolidation, lowering the exercise price from USD $42.93 to USD $5.00. If the company's stock price exceeds USD $6.50 for ten consecutive trading days, warrant holders must exercise their options within 30 days or face expiration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
none
-
Rhea-AI Summary

XORTX Therapeutics Inc. announces the amendment of 1,024,099 outstanding common share purchase warrants by changing the exercise price to USD $5.00 per share. The TSX Venture Exchange approved the amendments related to Private Placements from 2021 to 2022. Additionally, a new Warrant Acceleration Provision was introduced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
none
Rhea-AI Summary
XORTX Therapeutics Inc. announces the publication of a research paper in the American Journal of Physiology-Renal Physiology focusing on the effects of increasing serum uric acid on Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study reveals that elevated uric acid levels can significantly impact cyst growth and kidney size in ADPKD, potentially accelerating disease progression. The research also highlights the potential benefits of XORTX's XORLO™ in attenuating these effects, offering new insights into the treatment of ADPKD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
Rhea-AI Summary
XORTX Therapeutics Inc. welcomes Abigail Jenkins, a biotech industry veteran, to its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in delivering life-enhancing therapies. She has held key positions at various biopharmaceutical companies and holds a Master of Science in biotechnology. XORTX has granted 8,000 stock options to Ms. Jenkins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
management
-
Rhea-AI Summary
XORTX Therapeutics Inc. announces participation in investor conferences, engagement of LHA Investor Relations for services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
none
Rhea-AI Summary
XORTX Therapeutics Inc. announces the addition of Dr. Ronald Perrone to its Clinical Advisory Board, enhancing the expertise in treating autosomal dominant polycystic kidney disease (ADPKD). Dr. Perrone's vast experience in nephrology and clinical research will benefit the company's advanced clinical program, particularly the XRX-OXY-201 registration trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
management
-
Rhea-AI Summary
XORTX Therapeutics Inc. reports significant progress in 2023, achieving key milestones in the development of therapies for kidney diseases. The Company received U.S. Orphan Drug Designation for the XRx-008 program for ADPKD, aligning endpoints for accelerated approval. XORTX made advancements in chemistry, manufacturing, and clinical studies, aiming to conduct a registration clinical trial in 2024. Notable achievements include FDA and EMA regulatory submissions, patent advancements, and organizational enhancements. The independent commercial assessment forecasts potential worldwide peak sales exceeding $1B annually for the XRx-008 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) announces the submission of a new patent for the treatment of chronic kidney disease, focusing on innovative therapies to treat progressive kidney disease. The patent outlines new formulations and methods for safer and more effective use of xanthine oxidase inhibitors (XOI) in the setting of CKD, including autosomal dominant polycystic kidney disease, diabetic nephropathy, IgA nephropathy, lupus nephritis, and focal segmental glomerulosclerosis. Positive topline results from the XRX-OXY-101 bridging pharmacokinetic clinical study reported substantial increases in the bioavailability of oxypurinol with the XORLO™ formulation platform, increased dose proportionality compared to non-formulated oxypurinol, and achieved therapeutic target values. These results will facilitate precise dosing recommendations for upcoming registration trials in individuals with progressing kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.18%
Tags
none
Rhea-AI Summary
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen. Mr. Treanor, a seasoned pharmaceutical industry executive, brings valuable experience to the Company. XORTX is preparing for the potentially pivotal Phase 3 study of XRx-008 in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
management

FAQ

What is the current stock price of XORTX Therapeutics (XRTX)?

The current stock price of XORTX Therapeutics (XRTX) is $1.444 as of November 1, 2024.

What is the market cap of XORTX Therapeutics (XRTX)?

The market cap of XORTX Therapeutics (XRTX) is approximately 4.6M.

What is XORTX Therapeutics Inc.?

XORTX Therapeutics Inc. is a bio-pharmaceutical company focused on developing and commercializing therapies to treat progressive kidney diseases worldwide.

What are the main diseases XORTX targets?

XORTX targets progressive kidney diseases such as diabetic nephropathy, polycystic kidney disease, and complications from diabetes and cardiovascular diseases.

Where is XORTX Therapeutics headquartered?

XORTX Therapeutics Inc. is headquartered in Calgary, Canada.

What is TMX-049?

TMX-049 is a xanthine oxidoreductase inhibitor being developed by XORTX in collaboration with Teijin Pharma Limited.

Who are XORTX's strategic partners?

XORTX has strategic partnerships with Teijin Pharma Limited and the Icahn School of Medicine.

What stage is XORTX Therapeutics in?

XORTX Therapeutics Inc. is a clinical-stage biotechnology company.

What health issues does XORTX aim to address?

XORTX aims to address health issues related to aberrant purine and uric acid metabolism, such as diabetic nephropathy, hypertension, insulin resistance, and metabolic syndrome.

What is the focus of XORTX's pipeline?

The focus of XORTX's pipeline includes developing therapies to slow or reverse chronic kidney diseases and addressing acute kidney injury due to respiratory virus infections.

What are xanthine oxidase inhibitors?

Xanthine oxidase inhibitors are a class of drugs that reduce uric acid production and are being developed by XORTX to manage conditions like diabetic nephropathy.

How does XORTX contribute to COVID-19 research?

XORTX collaborates with the Icahn School of Medicine to study acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

XORTX Therapeutics Inc.

Nasdaq:XRTX

XRTX Rankings

XRTX Stock Data

4.61M
3.22M
3.35%
6.37%
0.01%
Biotechnology
Healthcare
Link
United States of America
Alberta Beach